BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
1 Service d’Hématologie, Pavillon Marcel Bérard 1G, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, Lyon- Pierre Bénite 69495, France
2 Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
3 Institut Bergonie, Bordeaux, France
4 Centre Hospitalier de Troyes, Troyes, France
5 Centre Hospitalier de Carcassonne, Carcassonne, France
6 Centre Hospitalier de Montauban, Montauban, France
7 Clinique Sainte Anne, Strasbourg, France
8 Polyclinique Montréal, Carcassonne, France
9 Clinique Pasteur, Evreux, France
10 Clinique Rambot-Provencale, Aix en Provence, France
11 Centre Hospitalier d'Aix en Provence, Aix en Provence, France
12 Centre Hospitalier Régional Universitaire de Tours, Tours, France
13 Clinique du Cap d’Or, La Seyne sur Mer, France
14 Centre Frédéric JOLLIOT, Rouen, France
15 Centre Hospitalier de Montbéliard, Montbeliard, France
16 Laboratoire HOSPIRA France, Meudon La Foret, France
BMC Cancer 2014, 14:503 doi:10.1186/1471-2407-14-503Published: 10 July 2014
The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of chemotherapy-induced anaemia (CIA) in the clinical setting.
Patients >18 years with CIA (haemoglobin [Hb] <11 g/dL) in association with solid tumours, lymphoma or myeloma and eligible for treatment with an epoetin biosimilar were included in this study. Patient characteristics were recorded at baseline along with anaemia-related information, such as observed and target Hb (as chosen by the treating clinician), brand and dose of epoetin biosimilar prescribed, and details of any other treatments. Patients were then followed-up at 3 and 6 months. The primary endpoint was Hb response (defined as Hb reaching ≥10 g/dL, an increase of Hb ≥1 g/dL since inclusion visit or reaching physician-defined target Hb, with no blood transfusions in the 3 weeks prior to measurement). Other endpoints included adverse events, achievement of target Hb and associated treatments.
Overall, 2333 patients >18 years (mean age 66.5 years) with CIA (haemoglobin [Hb] <11 g/dL) in association with solid tumours, lymphoma or myeloma and eligible for biosimilar epoetin treatment were included. 99.9% of patients received epoetin zeta (median dose 30,000 IU/week). Mean baseline Hb was 9.61 g/dL, with 35.6% of patients having moderate anaemia (Hb 8–9.5 g/dL). Hb response was achieved in 81.6% and 86.5% of patients at 3 and 6 months, respectively. Overall mean change in Hb level was 1.52 ± 1.61 and 1.72 ± 1.61 g/dL at 3 and 6 months, respectively. Transfusion and thromboembolic event rates were 9.4% and 2.4% at 3 months, and 5.8% and 1.5% at 6 months, respectively.
Epoetin zeta was effective and well tolerated in the management of CIA in patients with solid tumours, lymphoma and myeloma.
Trial registration number: NCT02140736 (date of registration: 14 May 2014).